Search
Ginseng
go.drugbank.com/drugs/DB01404ApprovedInvestigationalNutraceuticalGinseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties
Mixtures: GINSENG-E CAPSULESynonyms: Ren shen, Ren seng rootExbivirumab
go.drugbank.com/drugs/DB17747ExperimentalExbivirumab is an investigational monoclonal antibody. … It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]
Sargramostim
go.drugbank.com/drugs/DB00020ApprovedInvestigationalSargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues.
Recombinant Human Thrombopoietin
go.drugbank.com/drugs/DB16364Investigational[A225691, A225696] This drug is used in the treatment of thrombocytopenia.
Rosmarinic acid
go.drugbank.com/drugs/DB16865InvestigationalCategories: Compounds used in a research, industrial, or household settingPR-15
go.drugbank.com/drugs/DB06037InvestigationalPR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.
Forodesine
go.drugbank.com/drugs/DB06185InvestigationalForodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic
BACTEK-R
go.drugbank.com/drugs/DB16526InvestigationalMV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. … Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.
Tozorakimab
go.drugbank.com/drugs/DB16473InvestigationalTozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in